Guardant Health, Inc. (NASDAQ:GH) Shares Bought by GSA Capital Partners LLP

GSA Capital Partners LLP raised its position in Guardant Health, Inc. (NASDAQ:GH) by 269.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,291 shares of the company’s stock after acquiring an additional 22,828 shares during the quarter. GSA Capital Partners LLP’s holdings in Guardant Health were worth $646,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of GH. Vanguard Group Inc. grew its position in Guardant Health by 1.4% in the 3rd quarter. Vanguard Group Inc. now owns 10,950,230 shares of the company’s stock valued at $324,565,000 after acquiring an additional 146,902 shares in the last quarter. Exchange Traded Concepts LLC grew its position in shares of Guardant Health by 5.7% during the fourth quarter. Exchange Traded Concepts LLC now owns 37,696 shares of the company’s stock worth $1,020,000 after buying an additional 2,042 shares in the last quarter. Values First Advisors Inc. grew its position in shares of Guardant Health by 15.1% during the fourth quarter. Values First Advisors Inc. now owns 35,135 shares of the company’s stock worth $950,000 after buying an additional 4,604 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Guardant Health by 208.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,652 shares of the company’s stock worth $369,000 after buying an additional 9,231 shares in the last quarter. Finally, International Assets Investment Management LLC acquired a new position in shares of Guardant Health during the fourth quarter worth about $326,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Guardant Health Price Performance

Shares of NASDAQ GH opened at $31.07 on Friday. The company has a current ratio of 5.95, a quick ratio of 5.66 and a debt-to-equity ratio of 16.70. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $41.06. The stock has a 50 day moving average of $27.12 and a two-hundred day moving average of $23.03. The stock has a market cap of $3.80 billion, a P/E ratio of -7.93 and a beta of 1.13.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.94) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.94). Guardant Health had a negative return on equity of 246.47% and a negative net margin of 76.34%. The company had revenue of $168.49 million during the quarter, compared to analysts’ expectations of $150.51 million. On average, research analysts forecast that Guardant Health, Inc. will post -3.31 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on GH. Stephens reissued an “overweight” rating and set a $44.00 price objective on shares of Guardant Health in a research report on Friday, May 24th. Jefferies Financial Group began coverage on Guardant Health in a research report on Monday, June 3rd. They set a “buy” rating and a $32.00 price objective for the company. The Goldman Sachs Group lowered their price objective on Guardant Health from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, April 15th. Craig Hallum assumed coverage on Guardant Health in a research note on Wednesday, April 24th. They set a “buy” rating and a $28.00 target price for the company. Finally, Guggenheim upgraded Guardant Health from a “neutral” rating to a “buy” rating and set a $36.00 target price for the company in a research note on Friday, June 28th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $36.83.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.